Actively Recruiting

Age: 8Years +
All Genders
ID05250037

The Longitudinal Impact of Respiratory Viruses on Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Cell Transplantation (The RV-BOS Study)

Led by Fred Hutchinson Cancer Center ยท Updated on 2026-05-11

250

Participants Needed

4

Research Sites

26 weeks

Total Duration

On this page

Sponsors

F

Fred Hutchinson Cancer Center

Lead Sponsor

N

National Heart, Lung, and Blood Institute (NHLBI)

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are studying whether respiratory viruses cause lung diseases like bronchiolitis obliterans syndrome (BOS) or lung graft-versus-host disease in patients who have received donor stem cell transplants. Patients with chronic graft-versus-host disease (cGVHD) have a higher risk of BOS, and early respiratory viral illnesses after transplant may increase the chance of later lung problems. Monitoring lung function closely could benefit at-risk patients or those who already have BOS. Participants will use a handheld spirometer at home to measure lung function weekly and complete questionnaires. Every four weeks, they will provide nasal swabs for viral testing, and every three months, blood samples and nasal swabs will be collected. This monitoring will continue for up to two years, with at least one year required, plus an optional one-year extension. During the study, participants will regularly perform lung function tests at home, submit samples for viral and blood analysis, and complete health questionnaires. Researchers will track the occurrence of BOS and lung impairment, measure lung function decline, and study viral infections over time. The study aims to better understand lung disease development after transplant and improve early detection through home monitoring.

CONDITIONS

Brief Title

The Longitudinal Impact of Respiratory Viruses on Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Cell Transplantation (The RV-BOS Study)

Who Can Participate

Age: 8Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Allogeneic hematopoietic cell transplant recipients of any age 8 years or older
  • Patients with chronic graft-versus-host disease (cGVHD) within 5 years of diagnosis or increased risk for bronchiolitis obliterans syndrome (BOS)
  • Patients at Day 80 posttransplant with lung function decline or respiratory viral infection
  • Newly diagnosed BOS within 6 weeks of clinical recognition
  • Ability to use an Android or iOS smartphone with Wi-Fi
  • Willing and able to communicate electronically in English or Spanish
Not Eligible

You will not qualify if you...

  • Diagnosis of BOS at time of enrollment for Cohort 1
  • Life expectancy less than 2 years
  • Active blood cancer relapse or malignancy requiring treatment that interferes with study
  • Acute active lower respiratory tract infection or noninfectious respiratory condition at enrollment
  • Inability or unwillingness to perform study procedures at home
  • No personal iOS or Android smartphone
  • Unable or unwilling to communicate electronically

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person or remote)

Monitoring

Duration - Up to 2 years

Participants perform weekly home spirometry measurements and complete weekly questionnaires to monitor lung function and symptoms.

Weekly home measurements and questionnaires

Surveillance

Duration - Up to 2 years

Participants undergo nasal swabs every 4 weeks for viral polymerase chain reaction (PCR) surveillance to detect respiratory viruses.

Nasal swabs every 4 weeks

Sample Collection

Duration - Up to 2 years

Participants provide blood samples and nasal swabs every 3 months for further analysis related to lung health and viral infections.

Blood and nasal swab collection every 3 months

Trial Site Locations

Total: 4 locations

1

Stanford Cancer Institute

Palo Alto, California, United States, 94304

Actively Recruiting

2

University of Michigan Cancer Center

Ann Arbor, Michigan, United States, 48109

Actively Recruiting

3

MD Anderson Cancer Center

Houston, Texas, United States, 77030

Actively Recruiting

4

Fred Hutch/University of Washington Cancer Consortium

Seattle, Washington, United States, 98109

Actively Recruiting

Loading map...

Research Team

G

Guang-Shing Cheng, MD

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Similar Trials

A Phase I/II Study Evaluating Escalating Doses of 211At-Labe...

Acute Lymphoblastic Leukemia in Remission

Actively Recruiting

1 location

Letermovir Prophylaxis for Cytomegalovirus Infection After S...

Hematopoietic and Lymphoid Cell Neoplasm

Actively Recruiting

29 locations

Randomized Pilot Study of Two Doses of Cord Blood Tissue-Der...

Hematopoietic and Lymphoid Cell Neoplasm

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here